10-K: Fractyl Health Faces Going Concern Doubt Amidst Strategic Shift

Fractyl Health, a clinical-stage metabolic therapeutics company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, despite advancing its Revita and Rejuva product candidates.

Summary

• Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D).
• The company's lead product candidate, Revita DMR System (Revita), is designed to remodel the duodenal lining for weight maintenance after GLP-1 based therapy discontinuation.
• Revita has received U.S. FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 based therapy.
• The company anticipates submitting a potential De Novo marketing application for Revita in late Q4 2026, following favorable FDA feedback on its classification request.
• The REMAIN-1 study, evaluating Revita for weight maintenance, completed randomization of its 315-participant pivotal cohort in February 2026, with topline 6-month data expected in early Q4 2026.
• The Rejuva platform is developing novel, locally administered adeno-associated virus (AAV)-delivered pancreatic gene therapies, with RJVA-001 targeting T2D remission and RJVA-002 targeting obesity.
• Clinical Trial Applications (CTAs) for RJVA-001 were submitted in the EU (Netherlands) and Australia in H2 2025, with regulatory feedback expected in Q2 2026 and first-in-human dosing anticipated in H2 2026.
• RJVA-002, a dual GIP/GLP-1 gene therapy, is in preclinical development and demonstrated approximately 30% weight loss over five weeks in a preclinical obesity mouse model.
• A Strategic Reprioritization in January 2025 paused additional investment in Revita programs for T2D (REVITALIZE-1 study and Germany Real-World Registry study) and resulted in a workforce reduction of 22 employees (approximately 17%).
• The company reported a net loss of $141.0 million for the year ended December 31, 2025, an increase from $68.7 million in 2024, and an accumulated deficit of $556.3 million as of December 31, 2025.
• Cash and cash equivalents totaled $81.5 million as of December 31, 2025, which, combined with $4.1 million from subsequent warrant exercises, is projected to fund operating expenses into early 2027.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year from the filing's issuance date, partly due to potential non-compliance with a minimum liquidity covenant by the end of 2026 without additional financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to substantial net losses, a growing accumulated deficit, and explicit disclosure of 'substantial doubt about our ability to continue as a going concern,' despite positive clinical data and recent capital raises.

Positives

• Revita DMR System received U.S. FDA Breakthrough Device designation for weight maintenance in obesity patients discontinuing GLP-1 based therapy, potentially expediting development and review.
• Favorable FDA feedback on the De Novo classification request for Revita, indicating consistency with a Class II device classification.
• The REMAIN-1 Pivotal Cohort (n=315) completed randomization in February 2026, a significant milestone towards potential market authorization.
• The REVEAL-1 Cohort (n=22) showed stable weight maintenance (mean 1.5% total body weight change at 6 months) and minimal HbA1c change (0.04%) after Revita procedure post-GLP-1 discontinuation, contrasting with typical weight and metabolic rebound.
• The REMAIN-1 Midpoint Cohort (n=45) met its 3-month efficacy endpoint with strong statistical significance (p=0.014), demonstrating 2.5% further weight loss with Revita versus 10% weight regain in sham-treated participants.
• Exploratory analysis in the Midpoint Cohort indicated that Revita-treated participants with above median GLP-1-induced weight loss who received greater than 14 cm duodenal ablation retained 88% of GLP-1 induced weight loss at six months, compared to 60% in sham participants.
• The Rejuva gene therapy platform is advancing, with RJVA-001 CTAs submitted in the EU and Australia in H2 2025, moving towards anticipated first-in-human studies.
• RJVA-002, a dual GIP/GLP-1 gene therapy, demonstrated approximately 30% weight loss over five weeks in a preclinical obesity mouse model, highlighting its potential.
• The Germany Real-World Registry study showed durable weight loss (mean 8.0% at 1 year, 7.9% at 2 years for n=14) and HbA1c reduction (mean 1.0% at 1 year, 1.7% at 2 years for n=14) with Revita, with 86% of participants on stable or reduced GLAs at 2 years.
• High patient satisfaction was reported in the Germany Real-World Registry study, with 97% (1 year) and 93% (2 years) of participants stating they would undergo the Revita procedure again, and 100% (1 year) and 93% (2 years) recommending it to family or friends.
• The company successfully raised approximately $85.4 million in net proceeds from equity offerings (ATM, August, and September offerings) and $19.7 million from warrant exercises in 2025.
• Existing cash and cash equivalents, combined with recent warrant exercise proceeds, are expected to fund operating expenses and capital expenditure requirements into early 2027, covering multiple key clinical and regulatory milestones.

Negatives

• The company incurred a significant net loss of $140.95 million for the year ended December 31, 2025, an increase from $68.69 million in 2024.
• The accumulated deficit reached $556.3 million as of December 31, 2025, indicating substantial historical losses.
• Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date of the financial statements.
• The company may not be able to comply with the minimum liquidity covenant of $10.0 million related to its 2023 Notes by the end of 2026 without securing additional financing.
• No revenue was generated in 2025, a decrease from $93,000 in 2024, due to the pausing of the Germany commercial pilot as part of the Strategic Reprioritization.
• The company recorded a significant non-cash loss of $40.9 million from the change in fair value of warrant liabilities and a $4.7 million loss from the change in fair value of notes payable in 2025.
• The Strategic Reprioritization in January 2025 led to a workforce reduction impacting 22 employees (approximately 17% of the workforce).
• The company relies on third-party sole-source suppliers for certain sub-assembly components of Revita and materials for the Rejuva gene therapy platform, increasing supply chain risk.
• The company has never obtained marketing authorization for a product candidate in the U.S., introducing regulatory uncertainty for its lead candidates.
• The medical device and biopharmaceutical industries are highly competitive, with many larger and better-funded companies.
• The company has not yet studied the ability of Revita to be used in repeated procedures, which could negatively impact its long-term clinical utility and commercial adoption.

Risks

• The company has a limited operating history in developing medical devices and biopharmaceutical products, has not completed any pivotal clinical studies, and has no products approved for commercial sale in the U.S., making it difficult to evaluate its current business and predict future success and viability.
• The company has incurred significant net losses since inception, expects to continue to incur significant net losses for the foreseeable future, and may never achieve or sustain profitability, with identified conditions and events raising substantial doubt about its ability to continue as a going concern.
• Substantial additional capital is required to execute the operating plan and continue as a going concern; inability to raise such capital when needed or on acceptable terms may force delays, reductions, or elimination of research and drug development programs or future commercialization efforts.
• The regulatory clearance and certification processes of the FDA, comparable foreign regulatory authorities, and notified bodies are lengthy, time-consuming, and inherently unpredictable, with no guarantee of obtaining marketing authorization or that any authorization will be for a broad indication.
• Clinical studies are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome, with potential for substantial delays.
• The FDA or comparable foreign regulatory authorities may not accept data from clinical studies conducted outside the U.S., necessitating additional costly and time-consuming studies.
• Delays, interruptions, or additional costs in obtaining and maintaining government regulatory approvals, licenses, certifications, or reimbursements may occur due to federal government shutdowns, reduced staffing, or funding lapses.
• The company may not be able to submit Investigational Device Exemptions (IDEs) or Investigational New Drug Applications (INDs) or comparable documents on expected timelines, or regulatory authorities may not permit proceeding with additional clinical studies.
• The company is substantially dependent on the success of its lead product candidate, Revita, and its lead gene therapy product candidate, RJVA-001; failure to obtain marketing authorization or certification and commercialize them in a timely manner will harm the business.
• Long-term prospects depend on discovering, developing, and commercializing product candidates, which may fail in development or suffer delays adversely affecting commercial viability.
• Additional time may be required to develop and obtain regulatory approval or certification for Rejuva gene therapy candidates because they are expected to be regulated as a combination product.
• There is no certainty that Rejuva gene therapy candidates will successfully complete preclinical and clinical studies, or that they will not cause significant adverse events or toxicities.
• The company may not be able to gain the support of leading hospitals and key thought leaders, or to publish clinical study results in peer-reviewed journals, making it difficult to establish Revita DMR procedure and/or Rejuva gene therapy candidates as a standard of care.
• The ability of Revita to be used in repeated procedures has not yet been studied; failure to demonstrate safety and improved glycemic effects for repeat use could materially adversely affect clinical utility and commercial adoption.
• The company has never obtained marketing authorization for a product candidate in the U.S. and may be unable or delayed in obtaining it.
• Substantial reliance on third parties, including independent clinical investigators and Contract Research Organizations (CROs), to conduct preclinical and clinical studies; failure to perform contractual duties or comply with regulations could substantially harm the business.
• If new collaborations cannot be established on commercially reasonable terms, the company may have to alter its development and commercialization plans.
• Reliance on third parties for the manufacture and supply of sub-assembly components for Revita and materials for Rejuva gene therapy platform increases the risk of insufficient quantities or unacceptable costs.
• Failure of the company or its suppliers to comply with FDA's quality system and/or good manufacturing practice regulations could impair the ability to market products.
• The company faces the risk of product liability claims that could be expensive, divert management's attention, and harm its reputation and business; adequate product liability insurance may not be maintained.
• Reliance on a variety of intellectual property rights; inability to obtain, maintain, or protect intellectual property will harm the business.
• Inability to establish sales or marketing capabilities or enter into agreements with third parties to sell or market product candidates may prevent successful commercialization.
• Unfavorable global economic conditions, geopolitical events, and potential future public health crises could adversely affect the business.
• The ability to utilize net operating loss carryforwards, research and development tax credit carryforwards, and certain other tax attributes may be limited due to ownership changes under Section 382 of the Internal Revenue Code.
• Product candidates may cause serious adverse events or undesirable side effects, leading to suspension/discontinuation of clinical studies, delay/prevention of regulatory approval, or significant negative consequences post-marketing approval.
• Previous clinical studies involving viral vectors for gene therapy have shown serious adverse events, including leukemia due to insertional oncogenesis; if Rejuva vectors demonstrate a similar effect, clinical development may be halted or delayed.
• Breakthrough Device designation for Revita does not guarantee faster development or regulatory approval.
• If healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed with products, if approved, such products will not likely be widely used.
• Obtaining and maintaining regulatory approval or certification in one jurisdiction does not guarantee success in others.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and penalties for non-compliance.
• The company may be subject to enforcement action if it engages in off-label promotion of its products.
• Current and potential future use of artificial intelligence technologies may not be successful and presents new risks and challenges.
• Inability to develop new product candidates or enhance existing ones to keep pace with rapidly changing technology and customer requirements could adversely impact revenue.
• If the market opportunity for any product candidate is smaller than believed, revenue may be adversely affected.
• If the quality of product candidates does not meet expectations, brand and reputation could suffer.
• The sales cycle will be lengthy and variable, making revenue forecasting difficult.
• The training required for endoscopists to use Revita could reduce market acceptance.
• The company has never commercialized a product candidate and may lack the necessary expertise, personnel, and resources.
• Dependence on information technology systems; any failure or security/data privacy breaches could harm the business.
• Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of Rejuva gene therapy candidates.
• Operations are vulnerable to interruption by fire, severe weather, power loss, telecommunications failure, terrorist activity, future pandemics, and other events beyond control.
• As an emerging growth company and smaller reporting company, reduced reporting requirements may make common stock less attractive to investors.
• The requirements of being a public company may strain resources, result in more litigation, and divert management's attention.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Changes in the effective tax rate or tax liability may have an adverse effect on results of operations.
• Subject to various risks relating to international operations, which could adversely affect operating results.
• New tax legislation may impact results of operations and financial condition.
• Taxing authorities may successfully assert that sales and use, value added, or similar taxes should have been collected.
• Intellectual property litigation could cause substantial resource expenditure and distract personnel.
• Commercial success depends significantly on operating without infringing third-party intellectual property rights.
• Changes in patent law could diminish the value of patents in general.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and non-compliance could reduce or eliminate protection.
• Patent terms may not be sufficient to effectively protect product candidates and business for an adequate period of time.
• If trademarks and trade names are not adequately protected, the company may not be able to build name recognition.
• Inability to protect the confidentiality of trade secrets and other proprietary information may harm business and competitive position.
• May be subject to claims asserting employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of former employers or claims asserting ownership of the company's intellectual property.
• Loss of rights to licensed intellectual property could prevent continued development or commercialization of a product candidate.
• Numerous factors may limit any potential competitive advantage provided by intellectual property rights.

Future Outlook

The company anticipates submitting a potential FDA De Novo marketing application for Revita in post-GLP-1 weight maintenance in late Q4 2026. Regulatory feedback on CTAs for RJVA-001 is expected in Q2 2026, with first-in-human dosing and preliminary data anticipated in H2 2026, subject to CTA authorization. The company plans to execute an efficient hub-and-spoke commercialization strategy for Revita if approved, focusing on centers of excellence, targeted sales, and robust procedural training. It also intends to work with CMS and private insurers to establish coverage and reimbursement. Future plans include broadening Revita's indications to other metabolic diseases and expanding the Rejuva platform to other metabolic targets. Research and development expenses are expected to decrease in the near term due to the completion of REMAIN-1 randomization, partially offset by costs for the Rejuva first-in-human study. Selling, general, and administrative expenses are expected to remain stable in the near term but will increase with commercialization efforts.

Management Comments

• Management believes that our available cash and cash equivalents balance of $81.5 million as of December 31, 2025, combined with $4.1 million in subsequent proceeds from Tranche A warrant exercises received in January 2026, will be sufficient to fund our operating expenses and capital expenditure requirements into early 2027, through multiple key clinical and regulatory milestones.
• Given the inherent risk and uncertainty of future cash flow estimates as well as the minimum liquidity covenant requirement, our management has concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.
• Our decision to pause these studies [REVITALIZE-1 and Germany Real-World Registry] was not driven by any safety or efficacy concerns.
• The Company believes Revita and Rejuva, if approved by relevant regulatory bodies, have the potential to revolutionize treatment across the spectrum of obesity and T2D, align the clinical and economic interest of key stakeholders around the long-term regression of metabolic disease, and, at their fullest potential, significantly reduce the burden of metabolic disease globally.
• We believe our product candidates are not only unique in their potential for disease modification, but also in their design for broad accessibility for large populations.

Industry Context

StockSavvy.ai notes that Fractyl Health operates in a rapidly evolving metabolic disease market, particularly in obesity and T2D, where current GLP-1 receptor agonist (GLP-1RA) drugs, while potent, face high discontinuation rates (over 50% within three months) and significant weight/metabolic rebound (e.g., ~14% weight regain in 52 weeks post-tirzepatide discontinuation). This creates a critical unmet need for durable weight maintenance and disease-modifying therapies that Fractyl Health aims to address with Revita and Rejuva. The company's focus on organ-level root causes (gut and pancreas) positions it against established pharmaceutical companies heavily invested in chronic management, offering a potentially differentiated approach in a market projected to reach $250 billion in drug sales by the end of the decade for obesity alone. The gene therapy space for metabolic diseases is also highly competitive but nascent, with few approved products, giving Fractyl Health an opportunity to be a first-mover in endoscopic pancreatic gene therapy.

Comparison to Industry Standards

• Revita's REVEAL-1 Cohort showed stable weight maintenance (mean 1.5% total body weight change at 6 months) and minimal HbA1c change (0.04%) after Revita procedure post-GLP-1 discontinuation, compared to published third-party studies reporting approximately 10% weight regain and approximately 0.4% increase in HbA1c by this time point after GLP-1 withdrawal alone (e.g., Eli Lilly's SURMOUNT-4 study with tirzepatide and Novo Nordisk's STEP-1 extension study with semaglutide).
• The REMAIN-1 Midpoint Cohort demonstrated 2.5% further weight loss with Revita versus 10% weight regain in sham-treated participants at 3 months, contrasting with the typical 5-6% (10-15 pounds) rebound seen in other third-party clinical studies such as SURMOUNT-4.
• Preclinical head-to-head studies of Rejuva gene therapy candidates demonstrated greater weight reduction in a diet-induced obesity (DIO) mouse model (27% for GLP-1 PGTx versus 21% for semaglutide at 28 days) and durable weight loss (25% at day 57 versus 2% for semaglutide withdrawal) compared to chronic administrations of semaglutide (the active agent in Ozempic and Wegovy).
• Rejuva's potential cost of goods sold of less than $10,000 per patient for local delivery of AAV capsid is compared favorably to the high economic value of gene therapy, with an estimated $10,000 price per year under the Institute for Clinical and Economic Review price benchmark.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not subject to any material legal proceedings.

Related Party Transactions

• The company entered into an exchange agreement with entities affiliated with Nantahala Capital Management on November 12, 2025, for pre-funded warrants.
• The company entered into a credit agreement with Symbiotic Capital Opportunities Holding, L.P. and Catalio Structured Opportunities AIV I LP (the 2023 Lenders) in September 2023.
• The company has entered into consulting agreements with physicians, including some who have ownership interests in the company.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and stock price volatility due to the company's financial condition and clinical trial outcomes, including the Nasdaq minimum bid price notice.
• Employees experienced a workforce reduction of 22 employees (17%) as part of the Strategic Reprioritization, which could impact morale and retention.
• Healthcare providers and hospitals may benefit from new procedural therapies (Revita, Rejuva) for obesity and T2D, but will require training and successful reimbursement pathways.
• Patients could gain access to new disease-modifying therapies for obesity and T2D, particularly for weight maintenance post-GLP-1 discontinuation and T2D remission.
• Creditors, specifically the 2023 Lenders, face the risk of the company not complying with its minimum liquidity covenant by the end of 2026 without additional financing.

Next Steps

• Receive regulatory feedback on CTAs for RJVA-001 in Q2 2026.
• Initiate first-in-human dosing of RJVA-001 and report preliminary data in H2 2026 (subject to CTA authorization).
• Report 1-year REVEAL-1 Cohort data in Q2 2026.
• Report 1-year REMAIN-1 Midpoint Cohort randomized data in Q3 2026.
• Report topline 6-month randomized data from REMAIN-1 Pivotal Cohort in early Q4 2026.
• Submit potential FDA De Novo marketing application for Revita in post-GLP-1 weight maintenance in late Q4 2026.
• Continue to follow existing participants in REVITALIZE-1 and Germany Real-World Registry studies per protocol and report outcomes.
• Seek additional funds through equity or debt financings or collaboration/licensing transactions.
• Build a U.S. based direct sales force for Revita's potential launch.
• Roll out a robust procedural training and support program for GI endoscopists.
• Work with CMS and private insurers to establish coverage and reimbursement for Revita.
• Evaluate potential partnerships and/or distributor relationships for Revita's commercialization in other global geographies.
• Pursue regulatory authorizations, approvals, and geographic expansion into international markets for Revita.
• Expand application of Rejuva platform to other metabolic targets beyond GLP-1 (e.g., PYY, amylin, glucagon).
• Assess the impact of ASU 2024-03 on consolidated financial statements.
• Early adopt ASU 2025-06 effective January 1, 2026.
• Regain compliance with Nasdaq minimum bid price requirement by September 9, 2026.
• ATM Sales Agreement termination effective April 6, 2026.

Key Dates

Recommendation

The explicit disclosure of 'substantial doubt about our ability to continue as a going concern,' coupled with significant and increasing net losses, a large accumulated deficit, and the risk of not meeting debt covenants, presents a highly unfavorable financial outlook. While clinical progress is noted, the financial instability outweighs the potential future benefits for a seasoned investor.

Keywords

Metabolic therapeutics, Obesity, Type 2 diabetes, GLP-1, Revita, Rejuva, Gene therapy, Medical device, Duodenal mucosal resurfacing, AAV, Clinical trials, FDA Breakthrough Device, De Novo classification, REMAIN-1, RJVA-001, RJVA-002, Preclinical development, Going concern, Capital raise, Financial performance, Intellectual property, Corporate governance, Biotechnology, Pharmaceutical